Periprosthetic joint infection.
Bhaveen H Kapadia, Richard A Berg, Jacqueline A Daley...
https://pubmed.ncbi.nlm.nih.gov/26135702/Actively Recruiting
Led by Virtua Health, Inc. · Updated on 2026-05-12
20
Participants Needed
2
Research Sites
26 weeks
Total Duration
Researchers are investigating how preoperative Cryoneurolysis affects pain control after autograft anterior cruciate ligament ACL reconstruction surgery. This procedure uses extreme cold to target nerves and reduce pain. The study compares standard care alone versus standard care plus Cryoneurolysis in patients undergoing ACL reconstruction with their own tendon. The goal is to understand if Cryoneurolysis can help manage postoperative pain and reduce narcotic use. Participants are randomly placed into one of two groups. Both groups receive standard ACL reconstruction along with a preoperative oral medication cocktail and nerve blocks, including adductor canal and popliteal or iPACK blocks. The intervention group also receives Cryoneurolysis treatment targeting specific knee nerves 7 to 10 days before surgery. All participants will follow standard pain management protocols throughout the study. During the 12-week study period, participants will attend follow-up visits where their leftover postoperative pain medication will be reviewed. They will complete surveys assessing knee activity, function, and symptoms. Researchers will measure opioid consumption at 1, 6, and 12 weeks after surgery and assess knee function using the IKDC Subjective Knee Evaluation Form. The study carefully monitors pain management outcomes and patient recovery over three months.
CONDITIONS
The Effect of Pre-Operative Cryoneurolysis on Post-Operative Narcotic Consumption in Patients Undergoing Autograft ACL Reconstruction
S
Sean Mc Millan, DO
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Virtua Health, Inc.
Lead Sponsor
Pacira Pharmaceuticals, Inc
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Usual care plus cryoneurolysis | Usual care only |
|---|---|---|
| What is it? | Patients receive the standard ACL reconstruction procedure, plus targeted cryoneurolysis of select sensory nerves in the knee before surgery. | Patients receive standard ACL reconstruction without additional nerve treatment prior to surgery. |
| Role in study | Investigational arm assessing whether pre-operative cryoneurolysis reduces post-operative narcotic use. | Active comparator receiving standard care as currently practiced. |
| Main intended use | To potentially reduce opioid use after ACL reconstruction and improve post-surgical pain control. | Standard approach for ACL reconstruction, where pain management follows usual protocols. |
| How is it given? | Cryoneurolysis is performed on nerves close to the knee (AFCN, SPBSN, IPBSN) using a freezing technique 7–10 days before surgery. | No additional intervention performed before standard ACL reconstruction surgery. |
| Evidence status | The effect of cryoneurolysis before ACL surgery on opioid use and pain is under current investigation in this population. Similar studies in knee arthroplasty and osteoarthritis show reduced opioid use and pain scores compared to placebo. | Usual care represents the current pain management pathway after ACL reconstruction, for which opioid use is common. No published ACL-specific studies identified for this cell. |
| Important risks | Cryoneurolysis has been well tolerated in studies of knee pain, with reported risks including skin bruising, numbness, nerve irritation, or rarely, frostbite; no serious safety signals identified in published studies for knee applications. | Risks are those associated with standard ACL reconstruction and routine post-operative care, such as surgical risks and opioid-related side effects. |
| Important limitations | Currently, there is limited data on the use of cryoneurolysis specifically for ACL reconstruction. Most published evidence comes from knee arthroplasty or osteoarthritis populations, so direct applicability to ACL repair is still uncertain. | Pain after ACL reconstruction is a known clinical challenge, and opioid-based management is common, but alternative approaches for pre-emptive pain control are still being studied. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 7 to 10 days
Participants randomized to the experimental group receive pre-operative cryoneurolysis treatment to their surgical knee 7 to 10 days before surgery.
1 visit (in-person)
Duration - Day of surgery
Participants undergo autograft ACL reconstruction surgery with pre-operative oral medication and nerve blocks administered on the day of surgery.
1 visit (in-person)
Duration - 12 weeks
Participants are monitored for post-operative opioid consumption and knee function using the IKDC Subjective Knee Evaluation Form.
3 visits at 1 week, 6 weeks, and 12 weeks post-surgery (in-person)
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Bhaveen H Kapadia, Richard A Berg, Jacqueline A Daley...
https://pubmed.ncbi.nlm.nih.gov/26135702/William M Mihalko, Anita L Kerkhof, Marcus C Ford...
https://pubmed.ncbi.nlm.nih.gov/33279353/Brian M Ilfeld, Jessica Preciado, Andrea M Trescot
https://pubmed.ncbi.nlm.nih.gov/27333989/R Radnovich, D Scott, A T Patel...
https://pubmed.ncbi.nlm.nih.gov/28336454/Vinod Dasa, Gabriel Lensing, Miles Parsons...
https://pubmed.ncbi.nlm.nih.gov/26875052/Brandon E Lung, Theofilos Karasavvidis, Abhinav K Sharma...
https://pubmed.ncbi.nlm.nih.gov/36143381/Virtua Health, Inc.
Lead Sponsor
Pacira Pharmaceuticals, Inc
Collaborating Sponsor